Toremifene

Toremifene is an antiestrogen medication classified as a selective estrogen receptor modulator, a group of drugs that bind the estrogen receptor and behave as estrogen blockers in some tissues and estrogen mimics in others ^[2]. Chemically it is a chlorinated triphenylethylene and a very close analogue of tamoxifen, differing by a single chlorine substitution, which is why it is sometimes called 4-chlorotamoxifen ^[1]. It belongs to the same first-generation SERM family as tamoxifen and clomifene ^[2].

Toremifene is approved for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors ^[1][3]. It was introduced in the United States in 1997, becoming the first new antiestrogen marketed there since tamoxifen arrived in the late 1970s, and it is now available generically ^[3]. In clinical comparisons it has shown efficacy broadly similar to tamoxifen, along with a high degree of cross-resistance, so a cancer that stops responding to one may not respond to the other ^[3]. Off-label, toremifene has been used for benign breast pain and for gynecomastia, including breast changes caused by antiandrogen therapy, and it has drawn unapproved use among bodybuilders seeking to counter the estrogenic side effects of anabolic steroids. It is taken by mouth as tablets, marketed chiefly under the name Fareston.

Toremifene is almost completely absorbed after oral dosing, is extensively bound to plasma proteins, and is metabolized in the liver by cytochrome P450 enzymes before being eliminated mainly in the feces; its long half-life of about five days means steady levels are reached only after several weeks ^[1]. Common side effects reflect its antiestrogen action and include hot flashes, sweating, nausea, and vaginal discharge ^[1]. More serious concerns include prolongation of the QT interval on the electrocardiogram, which can predispose to abnormal heart rhythms, along with venous blood clots, cataracts, and stimulation of the uterine lining that can raise the risk of endometrial overgrowth or cancer ^[4]. Because of the cardiac effect, it is used cautiously in people with QT-related risk factors.

Common side effects include hot flashes, sweating, nausea, and vaginal discharge or dizziness. More serious risks include blood clots and, like other SERMs, it carries a warning about QT prolongation affecting heart rhythm, so it's avoided in people with certain cardiac conditions. It should only be used under medical supervision, and off-label use carries these same risks without oversight.

Toremifene prolongs the QT interval in a dose and concentration dependent way, and that single property drives most of its interaction risk. Combining it with other QT prolonging drugs, such as class IA and class III antiarrhythmics, methadone, ondansetron, macrolides or fluoroquinolones, compounds the effect and the endpoint is torsades de pointes. Pharmacovigilance data show selective oestrogen receptor modulators including toremifene reported with long QT and ventricular arrhythmia several times more often than aromatase inhibitors.

Because toremifene is cleared principally by CYP3A4, the same danger is reachable pharmacokinetically. Ketoconazole raised toremifene AUC roughly three fold in healthy subjects, and clarithromycin, ritonavir, itraconazole and voriconazole behave similarly; strong inducers including rifampin, carbamazepine, phenytoin and St John's wort lower concentrations enough to threaten efficacy.

Toremifene also affects CYP2C9 substrates, so exposure to warfarin and phenytoin can rise, and thiazide diuretics, which reduce renal calcium excretion, raise the risk of hypercalcaemia in patients with bone metastases.

Checking a whole stack? Run it through interactions + stacks.